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Cytoplasmic islet cell antibodies are well-established 
predictive markers of IDDM. Although target molecules 
of ICA have been suggested to be gangliosides, 
human monoclonal ICA of the immunoglobulin G class 
(MICA 1-6) produced from a patient with newly 
diagnosed IDDM recognized glutamate decarboxylase 
as a target antigen. Here we analyzed the possible 
heterogeneity of target antigens of ICA by subtracting 
the GAD-specific ICA staining from total ICA staining 
of sera. This was achieved 1) by preabsorption of 
ICA + sera with recombinant GAD 6 5 and/or GAD 6 7 
expressed in a baculovirus system and 2) by ICA 
analysis of sera on mouse pancreas, as GAD 
antibodies do not stain mouse islets in the 
immunofluorescence test. We show that 24 of 25 sera 
from newly diagnosed patients with IDDM recognize 
islet antigens besides GAD. In contrast, GAD was the 
only islet antigen recognized by ICA from 7 sera from 
patients with stiff man syndrome. Two of these sera, 
however, recognized antigens besides GAD in Purkinje 
cells. In patients with IDDM, non-GAD ICA were 
diverse. One group, found in 64% of the sera, stained 
human and mouse islets, whereas the other group of 
non-GAD ICA was human specific. Therefore, mouse 
islets distinguish two groups of non-GAD ICA and lack 
additional target epitopes of ICA besides GAD. 
Longitudinal analysis of 6 sera from nondiabetic ICA + 
individuals revealed that mouse-reactive ICA may 
appear closer to clinical onset of IDDM in some 
individuals. Mouse-reactive ICAs, however, remained 
absent in 36% of the patients at diagnosis of IDDM. 
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The humoral immune response to islet cells in IDDM has been extensively studied, and two major groups of autoantibodies were estab-lished as highly predictive markers for the de-
velopment of the disease. Cytoplasmic ICAs were 
defined by an indirect immunofluorescence test on pan-
creas sections (1) and 64,000-M r antibodies were eval-
uated by an immunoprecipitation assay on in vitro-
labeled islet cells (2). The 64,000-H islet antigen was 
identified as the enzyme GAD (3), whereas islet antigens 
recognized by ICA were suggested to be monosialogan-
gliosides (4,5). The first evidence that ICA and 64,000-H 
antibodies were partly identical was demonstrated by the 
analysis of human monoclonal ICA of the IgG class 
(MICA 1-6) derived from a patient with newly diagnosed 
IDDM (6). These human monoclonal autoantibodies re-
vealed typical features of both ICA and 64,000-/Wr anti-
bodies and demonstrated that GAD is a target antigen of 
ICA (7). Whereas some ICA + IDDM sera, however, 
stained all cells of the islet, the GAD-specific MICA 
recognized predominantly ß-cells, consistent with the 
ß-cell-specific expression of GAD in islets (8,9). This 
indicated a heterogeneous composition of ICA in serum 
from patients with IDDM. A heterogenous composition of 
ICA was also suggested by a study describing species-
restricted ICA with different predictive value for develop-
ment of IDDM (10) and by a study describing ß-cell-
selective and -nonselective staining patterns of ICA + 
sera (11). 
Apart from IDDM, ICA and GAD-reactive autoantibod-
ies were described in sera from patients with the rare 
neurological disorder SMS, where GABA-ergic neurons 
rather than ß-cells are affected by the disease. Patients 
with SMS are frequently ICA + and some of them develop 
IDDM during the progress of the autoimmune disease 
(12). 
The aim of this study was to evaluate and further 
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characterize the heterogeneity of ICA in sera from newly 
diagnosed patients with IDDM and from patients with 
SMS. We analyzed ICA reactivity by 1) preabsorption of 
sera with human recombinant G A D 6 5 and G A D 6 7 before 
ICA analysis and 2) by analyzing reactivity with mouse 
pancreatic islets, which express low levels of GAD 
(7,13). The GAD-specific MICA had demonstrated that 
mouse islets express GAD at a level that is below the 
detection limit of the immunofluorescence test (24). We 
therefore assessed whether ICA analysis on mouse pan-
creas could be used as a short and simple method to 
distinguish GAD-reactive ICA from non-GAD-reactive 
ICA in sera from patients with IDDM. We found a heter-
ogeneous reactivity of ICA + sera to mouse islets, which 
did not correlate with the GAD-blocking data. Only a 
subgroup of non-GAD-reactive ICA were detected in 
mouse islets, which, we concluded, must lack additional 
typical target epitopes of ICA besides GAD. GAD-
reactive ICA as well as two different groups of non-GAD-
reactive ICA may, therefore, coexist in sera from patients 
with IDDM. 
RESEARCH DESIGN AND METHODS 
Sera were obtained with informed consent from 25 pa-
tients with newly diagnosed IDDM (mean age of 
20.7 ± 8.0 yr; range 11-33 yr) and from 7 ICA"*" patients 
with SMS (mean age 53.3 ± 12.6 yr; range 30-69 yr). 
One SMS patient (No. 4 in Table 1) had developed IDDM 
4 yr before the serum sample was taken. Serial serum 
samples were analyzed from 6 ICA + individuals (mean 
age 15.7 ± 2.4 yr; range 10-17 yr) over a period of 32 
mo. The individuals were characterized previously else-
where (14), and 3 of them developed IDDM during this 
time of follow-up. 
Antibody analyses. ICA were detected in patients' sera 
by the classical ICA test of indirect immunofluorescence 
on unfixed sections of human pancreas (blood group 0) 
as described previously (15). Quantification in JDF U was 
performed according to recommendations of the Second 
International ICA Workshop. Values >80 JDF U were 
calculated by extrapolation of the standard curve. ICA 
analysis on Balb/c mouse pancreas was perfomed with 
undiluted patients' sera as well as with 20 normal sera. 
Test specificity was 95%, and test sensitivity with the 
IDDM sera was 64%. 
Antibodies to GAD were determined in an immunopre-
cipitation assay (16). Recombinant baculovirus encoding 
for full-length human G A D 6 5 and G A D 6 7 was derived as 
described elsewhere (17). GAD was expressed in 
Spodoptera frugiperda (Sf9) cells by infection with re-
combinant virus. At 48 h after infection, Sf9 cells were 
labeled for 2 h with [35S]methionine in methionine-free 
Grace's medium. Cells were lysed with 20 mM Tris/HCI, 
pH 7.4, 1 mM phenyl-methyl-sulfonyl-fluoride, 1 mM 
amino-ethyl-isothiouronium-bromide, 0.02 mM pyridox-
al-phosphate, 1% Triton X100 and 2 |xg/ml of the pro-
teinase inhibitors leupeptin, aprotinin, bestatin, and 
pepstatin and incubated for 30 min on ice. After a spin at 
33,000 g for 30 min at 4°C, supernatant was precleared 
with Protein A Sepharose and normal human serum 
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followed by specific precipitation of GAD by the patients' 
serum as described previously (16). The expressed GAD 
proteins were derived in a native conformation and a fully 
restored autoantigenicity (17). In the first GAD antibody 
workshop, our assay revealed a sensitivity of 83.3% and 
a specificity of 100%. 
Blocking analyses. Blocking analyses were performed 
with baculovirus-expressed G A D 6 5 and G A D 6 7 unmixed 
or in a mixture of 3:1. Virus-infected cells were lysed 48 h 
after infection with 20 mM KH 2 P0 4 , 2 mM ethylen-diamin-
tetra-acetate, 2 mM amino-ethyl-isothiouronium-bro-
mide, 0.2 mM pyridoxalphosphate, and 1 mM phenyl-
methyl-sulfonyl-fluoride. Cell debris was removed at 
33,000 g for 30 min at 4°C, and supernatant was checked 
for protein content (18). Specific GAD enzyme activity of 
the supernatant was determined by a modification of the 
method described by Albers and Brady (19). Aliquots 
from homogenates were added to tubes containing 200 
Iii of 50 mM KH 2 P0 4 , 2 mM amino-ethyl-isothiouronium-
bromide, 0.2 mM pyridoxal-phosphate, 1 mM L-GIU, and 
0.1 jxCi L - [1 - 1 4 C ] G I U (59 mCi/mM) (Amersham, Amer-
sham, UK). A filter paper soaked with 50 |il of 1 M 
hyamine hydroxide was placed in the tubes. The tubes 
were closed immediately and incubated at 37°C for 60 
min. The reaction was terminated by injecting 1 ml of 5 N 
H 2 S0 4 . After a 1-h equilibration period, the 1 4 C 0 2 ab-
sorbed in the filter paper was counted in a liquid scintil-
lation counter. One unit of GAD was defined as 1 ixmol 
1 4 C 0 2 formed per minute per milligram of protein. 
For preincubation of sera before ICA analysis, 10 (xl of 
serum were incubated with optimized amounts of GAD 6 5 , 
GAD 6 7 , or a mixture of both (3:1) for 1 h at room 
temperature under gentle rotation. Corresponding vol-
umes of supernatant isolated from Sf9 cells infected with 
wild-type baculovirus expressing no GAD were used as 
a control. Twenty microliters of the blocking mixture were 
then applied in the indirect immunofluorescence test to 
evaluate residual ICA staining. SMS sera with titers 
>2560 JDF U were diluted 1:30 before blocking or for 
staining of mouse pancreas. 
RESULTS 
Blocking of ICA + sera with G A D 6 5 and G A D 6 7 . For 
subtraction of GAD reactivity from total ICA staining, we 
established a blocking assay requiring minimal dilution of 
sera by the blocking solution. The human monoclonal 
anti-GAD 6 5 antibody MICA 4 and a high-titered ICA + 
serum (SMS serum No, 3) positive for G A D 6 5 and GAD 6 7 
in the immunoprecipitation test were used to optimize 
blocking conditions. MICA 4 and the SMS serum were 
preabsorbed with increasing volumes of a mixture of 
G A D 6 5 and G A D 6 7 (3:1) before their ICA reactivity was 
quantitated by titration on human pancreas (Fig. 1). The 
titer of the SMS serum decreased rapidly with increasing 
amounts of GAD and was ablated by preincubation with 
20 |xU of the GAD mixture. The amount of GAD sufficient 
to block the ICA staining of MICA 4 was 5 ^U ; 40 f i l l of 
GAD was selected as the optimal blocking condition for 
further experiments. This required a dilution of the sera 
by the blocking mixture of only 1:4. 
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FIG. 1 . The GAD-spec i f i c human monoc lona l an t ibody MICA 4 and an 
I C A + se rum (SMS s e r u m No. 3 in Table 1) were p reabsorbed w i th 
increas ing vo lumes of a mix tu re of G A D 6 S and G A D 6 7 (3:1) as 
descr ibed in METHODS. ICA react iv i ty w a s quant i ta ted o n human 
pancreas. ICA react iv i ty of MICA 4 ( • ) was b locked b y p re incuba t ion 
w i th 5 t i l l of G A D . The t i ter of the SMS se rum decreased rap id ly after 
p re incubat ion w i th increas ing amoun ts of G A D ext racts (O). The 
con t ro l incubat ion of the SMS se rum w i th GAD- f ree bacu lov i rus 
ext racts ( • ) ref lects the d i lu t ion effect a t t r ibutab le to increas ing 
vo lumes of b l ock ing so lu t i on app l ied in the p re incuba t ion s tep (cont ro l 
not s h o w n for MICA 4). 
Prevalence of GAD-reactive antibodies. In 25 ICA + 
sera from patients with newly diagnosed IDDM, preva-
lence of GAD antibodies was determined in an immuno-
precipitation assay using human recombinant G A D 6 5 
and G A D 6 7 expressed in a baculovirus system. Of the 
sera, 15 were positive for G A D 6 5 and 3 were additionally 
positive for GAD 6 7 . ICA staining of only 1 of 25 sera could 
be blocked completely by preincubation with mixtures of 
G A D 6 5 and GAD 6 7 . Therefore, in all but 1 serum, non -
GAD-reactive ICA were detected. In contrast, the 7 sera 
from patients with SMS were all positive for G A D 6 5 and 
for G A D 6 7 in the immunoprecipitation assay, and ICA 
staining of all of them was completely blocked by prein-
cubation with a mixture of G A D 6 5 and G A D 6 7 (Table 1). 
However, when we modified the assay according to a 
procedure applied by Atkinson et al. (20) and diluted the 
GAD-positive IDDM sera before their end-point titer 
before blocking with GAD, we observed that 3 additional 
sera were completely blocked by GAD (IDDM sera no. 
11, 20, and 22). This indicates that GAD-reactive and 
non-GAD-reactive ICA are present in different titers in 
ICA + sera and reveals that GAD-reactive ICA represent 
the high titered ICA in 3 of the tested sera. In sum, GAD 
is the only islet antigen recognized by ICA from sera of 
patients with SMS, whereas additional islet antigens 
besides GAD are recognized by 96% of ICA + sera from 
newly diagnosed patients with IDDM. The serum of the 
only patient who had developed both SMS and IDDM 
behaved like all other SMS sera and was completely 
blocked by GAD. 
Isoform-specific blocking on islets and brain. All SMS 
sera and the single IDDM serum, which was completely 
blocked by a combination of G A D 6 5 and G A D 6 7 on islets, 
were analyzed for isoform-specific blocking on islets and 
cerebellum. Preincubation with G A D 6 5 resulted in a com-
plete ablation of ICA staining in islets for the IDDM serum, 
consistent with its GAD 6 5 specificity. Although all SMS 
sera were strongly positive for G A D 6 7 in the immunopre-
cipitation test, G A D 6 5 was sufficient to block their staining 
on islets, whereas preblocking with G A D 6 7 did not ablate 
their ICA staining. However, when the blocking assay 
was performed on sections of rat cerebellum, where both 
GAD forms are expressed in neurons positive for GABA 
(21), none of the SMS sera was completely blocked either 
by preincubation with G A D 6 5 or by preincubation with 
G A D 6 7 alone. Only a combination of both GAD forms 
ablated the staining of the GABA-ergic neurons in 5 of 7 
SMS sera. This demonstrated that GAD 6 5-specific as well 
as GAD 6 7-specific antibodies were present in at least 5 
SMS sera and that 2 SMS sera contained additional 
brain-specific antibodies that recognized antigen(s) dif-
ferent from GAD in GABA-ergic neurons. These antigens 
were not detected in human islet cells. The inconsistency 
of results obtained with preabsorbed SMS sera on brain 
and islets can only be explained by differences in the 
expression of both GAD forms in these tissues. As 
GAD 6 7-specific antibodies escaped detection in human 
islets, no G A D 6 7 seems to be expressed in human 
ß-cells. These data are consistent with a report from 
Karisen et al. (22) that detected only G A D 6 5 in human 
islets, which confirms our own results (J. Kim, W. R., S. 
Baekkeskov, unpublished observations) that only G A D 6 5 
is expressed in human islets. 
Heterogenous reactivity of ICA with mouse islets. 
Because of its low expression of both G A D 6 5 and GAD 6 7 , 
mouse pancreas is suitable for subtracting GAD reactiv-
ity from ICA + sera directly in the immunofluorescence 
test. Therefore we analyzed ICA reactivity of the IDDM 
and the SMS sera on mouse pancreas in comparison with 
ICA" normal human sera. The majority of sera revealed an 
unspecific background staining of exocrine cells of 
mouse pancreas that was independent of the conjugated 
secondary antibody used, the disease status, or the 
positivity of islets. This background staining seemed to 
be a limitation of mouse pancreas as the same unspecific 
staining was observed when the sera were analyzed on 
NOD mouse pancreas. Islets were evaluated as positive 
in our test when their staining was brighter than the dark 
cells of the exocrine pancreas. According to this crite-
rion, 1 normal control serum was weakly ICA"*" when 20 
ICA" normal human sera were analyzed on mouse pan-
creas. Among the ICA + SMS and IDDM sera analyzed, all 
SMS sera were ICA" on mouse islets (compare Fig. 2B 
and D), and IDDM sera behaved heterogenously. Only 
16 of 25 ICA + IDDM sera (64%) remained ICA + when 
tested on mouse tissue (Table 1 and Fig. 2A and B). For 
the SMS sera, ICA analysis on mouse pancreas con-
firmed the data obtained by blocking; only GAD-reactive 
ICA contributed to the ICA staining of these sera on 
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TABLE 1 
Antibody characteristics of ICA + sera and subtraction of GAD-specific staining 
Antibodies ICA staining 
ICA 
Age(yr) (JDF U) GAD 6 5 * GAD 6 7 * 
Blocked by G A D 6 5 On mouse 
plus G A D 6 7 islets 
IDDM subject 
1 16 20 + - - + 2 38 20 + - + -3 33 40 + + - + 4 11 40 - - + c 22 80 - - - -6 18 80 - + 7 19 80 + - — + 8 17 80 + - - + 9 36 80 + - - + 10 19 160 - -11 16 160 - -12 18 320 - - + 13 20 320 - -
14 18 320 - - - + 15 14 320 - - - -16 11 320 + + - -17 33 320 + - — + 18 18 320 + - - + 19 12 320 + - — + 20 31 320 + - - -21 11 640 — — - + 22 14 640 + - - -23 25 640 + - - + 24 26 1280 + - — + 25 22 1280 + + - + y/IS subject 
1 56 40 + + + — 
2 53 320 + + + -3 69 2560 + + + — 
4 11 2560 + + + -5 30 3200 + + + — 
6 59 5120 + + + -7 45 10240 + + + 
+ , positive; negative. 
*Determined by immunoprecipitation of G A D 6 5 or G A D 6 7 from baculovirus extracts. 
human pancreas. Among the diabetic sera, recognition 
of epitopes besides GAD became directly evident in 
64% of the sera by their reactivity with mouse islets. In the 
remaining sera, being negative on mouse islets, only 1 
serum was blocked by GAD in the blocking test. Non-
GAD-reactive ICA must, therefore, exist as well in the 
majority of IDDM sera, which do not show ICA reactivity 
on mouse islets. These data clearly demonstrate the 
existence of non-GAD ICA that do not react with mouse 
pancreas. In conclusion, mouse islets must lack addi-
tional target epitopes of ICA outside of GAD. Non-GAD 
ICA in individual sera of patients with IDDM may, there-
fore, be heterogeneously composed, and multiple islet 
antigens seem to provoke a humoral immune response 
during the course of ß-cell destruction in IDDM. 
Longitudinal analysis of ICA + sera. We followed the 
heterogeneity of ICA in 6 ICA + individuals, 3 of which 
became diabetic during the 32-mo follow-up. To assess 
the natural history of ICA reactivity in these sera, GAD 
reactivity was analyzed by immunoprecipitation, and ICA 
staining was followed on mouse and human pancreas 
with the indirect immunofluorescence test. The results 
are summarized in Table 2. All individuals were GAD-
antibody positive and remained ICA + on human pan-
creas throughout the follow-up. A heterogeneous 
reactivity of the sera was observed in the ICA test on 
mouse pancreas. Reactivity with mouse islets remained 
constantly negative or positive during the follow-up in 4 
individuals, 3 of which were tested around the onset of 
IDDM. One individual, however, was initially ICA" on 
mouse pancreas and became strongly positive after 1 yr. 
During this period, GAD antibodies disappeared from 
the serum. This individual revealed a pathological IVGTT 
(first-phase insulin response below the first percentile) 
throughout the observation period but did not progress to 
overt diabetes yet. In a second individual, a weak reac-
tivity on mouse pancreas turned into a strong positivity 
over a 6-mo period during which GAD antibodies re-
mained stable. So far, no pathological first-phase insulin 
response in the IVGTT was observed in this individual. 
DISCUSSION 
For a long time, ICA and 64,000-H antibodies were 
defined only by the method by which they were detected. 
According to the disconcordant prevalence of the two 
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FIG. 2. Indirect immuno f luo rescence s ta in ing per fo rmed o n un f ixed cryosta t sec t ions of human pancreas (A and B) and m o u s e pancreas (C and 
D) ob ta ined w i th se rum f r o m an I C A * pat ient w i t h IDDM and f r o m a pat ient w i t h SMS. The se rum f r o m the pat ient w i t h IDDM was pos i t i ve o n 
human and mouse is let ce l ls {A and C) . The SMS se rum, w h i c h w a s pos i t i ve fo r G A D 6 5 and G A D 6 7 in the immunoprec lp l ta t i on assay , w a s 
pos i t i ve o n h u m a n is le ts (B) bu t fa i led t o s ta in m o u s e is let ce l ls (D). Scale bar 100 jxm ( A B, and D ) ; sca le bar 64 y,m (C). 
antibody groups in sera, they were considered distinct 
entities with 64,000-/Wr antibodies recognizing an islet 
protein and cytoplasmic ICA recognizing a monosialo-
glycolipid (2,4). Several lines of evidence have now 
accumulated to a more complex view of these markers of 
autoimmune insulitis. 
Partial identity of ICA and 64,000-H antibodies be-
came evident from analysis of human monoclonal ICA of 
the IgG class (MICA 1-6) derived from a patient with 
IDDM (6). MICA 1-6 shared common features of ICA and 
64,000-H antibodies and identified GAD as a target 
antigen of ICA (7,8). In addition, heterogeneity of ICA 
became obvious by the predominantly ß-cell-specific 
staining pattern of the MICA in contrast to a staining of all 
islet cells in some ICA + sera (8). Heterogeneity of ICA 
was also suggested by a study distinguishing ICA + sera 
by staining pattern. A diffuse staining of all islet cells was 
described for some ICA + sera, whereas other ICA + sera 
gave a granular staining pattern of only ß-cells (11). 
Another report described species-restricted, ß-cell— 
specific ICA that did not react with mouse pancreas and 
revealed a lower degree of risk for progression to overt 
diabetes than other ICA called nonrestricted ICA. These 
nonrestricted ICA, in contrast, stained all islet cells and 
reacted with mouse pancreas (10). As our GAD-specific 
MICA stained predominantly ß-cells in islets (8) and 
lacked a reactivity with mouse islets (24), we speculated 
that GAD-reactive ICA may contribute for the ß-cell— 
restricted subgroups of ICA observed in these two stud-
ies. 
In this study, therefore, we investigated the possible 
hetereogeneity of ICA and the GAD reactivity of ICA in 25 
ICA + sera from newly diagnosed patients with IDDM. By 
combining three different tests we characterized three 
distinct subgroups of ICA present in sera from patients 
with IDDM. In addition to the GAD antibodies that were 
detected in 60% of these sera by an immunoprecipitation 
assay, we identified non-GAD ICA in 96% of the individ-
uals using a newly established GAD-blocking assay. By 
ICA analysis on mouse and human pancreas we further 
distinguished two different groups of non-GAD-reactive 
ICA in IDDM sera. One group, present in 64% of the sera, 
was reactive with mouse and human pancreas, whereas 
another group, present in at least 32% of the sera, did not 
recognize antigens in mouse islets. One possible expla-
nation for these data is that one additional target antigen 
of ICA besides GAD exists in both mouse and human 
islet cells. Non-GAD ICA reactive with mouse and human 
pancreas would then recognize mouse-human cross-
reactive epitopes in this antigen, whereas the other 
non-GAD ICA bind only human-specific epitopes in this 
antigen. Alternatively, ICA from IDDM sera recognize 
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TABLE 2 
Antibody characteristics of 3 prediabetic and 3 ICA + 
nondiabetic individuals followed over a 32-mo period 
ICA 
Sample Anti- Human 
Subject (mo of follow-up) G A D 6 5 (JDF U) Mouse 
A 0 + 160 + 
8 + 40 + 
24* + 160 + 
B 0 + 40 -12 + 10 -32 - 40 + C 0 + 80 -18* + 10 -32 + 40 -D 0 + 160 + 
12 + 160 + 
32 + 160 + 
E 0 + 80 (+) 
6 + 80 + + 
27 + 160 + + 
F 0 + 10 + 
9 + 5 + 
30* + 10 + 
- , negative; (+), weakly positive; +, positive; + + , strongly 
positive. 
*Time of onset of IDDM in prediabetic individuals. 
several additional antigens besides GAD, some of which 
are differentially expressed in mouse and human islet 
cells. A major difference in expression levels between 
mouse and human islets was already demonstrated for 
GAD (13). In sum, our results demonstrate that non-GAD 
ICA in IDDM are diverse and coexist in a single serum. 
The low expression of G A D 6 5 and G A D 6 7 in mouse 
pancreas does not provide a simple opportunity to dis-
tinguish GAD reactivity from all other ICA reactivities 
observed in IDDM sera. 
By using a blocking assay requiring minimal dilution of 
sera, we observed a 96% prevalence of non-GAD-
reactive ICA in IDDM sera. As the baculovirus-expressed 
GAD used for blocking demonstrated a fully restored 
antigenicity (17), the lack of correlation between blocking 
data and ICA staining of mouse islets is valid and not a 
result of uncorrect folding of the GAD used for blocking. 
In a previous study, Atkinson et al. (20) observed a 
prevalence of non-GAD-reactive ICA in 72% of new-
onset IDDM patients with the use of a blocking test, in 
which the sera were diluted before their end point before 
blocking with GAD. Applying such conditions for our 
IDDM sera, the detection of non-GAD-reactive ICA 
decreased to 84%. We conclude that different ICA exist 
at different titers in the sera. As non-GAD-reactive ICA 
were diluted out in 3 sera by dilution of the sera before 
blocking, GAD-reactive ICA contributed to the high ti-
tered ICA in these sera. 
ICA and GAD reactivity have been described in sera 
from patients with SMS, a condition that is sometimes 
associated with IDDM (12). Antibody reactivity in ICA + 
sera from patients with SMS was completely different 
from IDDM sera. All SMS sera reacted with both G A D 6 5 
and GAD 6 7 , and all ICA observed were GAD reactive. In 
IDDM, in contrast, both GAD forms were recognized by 
only 8% of the sera, and non-GAD-reactive ICA existed 
in 96% of the sera. A major difference in antibody status 
was therefore observed in the two diseases. Coincident 
with the lack of G A D 6 7 expression in human islets (22), 
GAD 6 7-reactive antibodies were rare in IDDM sera. In 
contrast, all SMS sera were autoreactive toward both 
forms of GAD, whereas G A D 6 7 and G A D 6 5 are both 
expressed in GABA-positive neurons (23). In addition, 2 
SMS sera contained additional neuron-specific antibod-
ies besides GAD antibodies. Although the number of 
patients with SMS tested is limited, these results indicate 
a heterogeneity of autoreactive antibodies occurring 
preferentially toward antigenic targets expressed at the 
site affected by the autoimmune disease: toward islets in 
IDDM and toward GABA-ergic neurons in SMS. Whether 
cross-reactivity of autoantibodies plays a role when pa-
tients with SMS develop IDDM is an interesting feature to 
be addressed. We analyzed ICA from serum of a patient 
with SMS who also suffered from IDDM and detected only 
GAD-reactive ICA. Because this serum was derived 4 yr 
after diagnosis of IDDM and no serum before or around 
onset of IDDM was available from this patient, it remains 
to be determined whether insulitis and precipitation of 
IDDM temporarily affect the heterogeneity of ICA in 
serum from patients with SMS. 
ICA cross-reactivity between mouse and human have 
been reported to stain all islet cells and to indicate a high 
risk for the development of IDDM in first-degree relatives 
of patients with IDDM (10). ICA lacking reactivity with 
mouse islets were, in contrast, shown to be ß-cell -
specific and to indicate a lower risk for progression to 
overt diabetes. In our study on ICA + newly diagnosed 
patients with IDDM, frequency of mouse-reactive ICA 
was only 64%. ICA detected on mouse islets therefore 
represented less sensitive markers for progression to 
overt disease than ICA detected on human islets. Be-
cause the previous study compared ICA reactivity on 
mouse and rat pancreas and we compared ICA reactivity 
on human and mouse tissue, the observed differences 
may relate to the substrate chosen. 
By natural history analysis of 6 ICA + individuals, we 
demonstrated that mouse-reactive ICAs may appear as 
additional markers closer to onset of IDDM but remain 
absent in some of the individuals that progress to overt 
diabetes. Atkinson et al. (20) observed in a longitudinal 
study on 3 individuals that GAD-reactive ICA turned into 
non-GAD-reactive ICA nearer to clinical onset of IDDM. 
The researchers therefore suggested that GAD antibod-
ies are markers of early ß-cell destruction, and non-GAD 
ICA may provide a marker for a more advanced lesion of 
islet cell destruction. Interestingly in one of our ICA + 
individuals with a pathological IVGTT, a conversion from 
GAD-reactive ICA to mouse-reactive non-GAD ICA was 
observed as well. This person has not, however, pro-
gressed to overt diabetes yet. Because mouse-reactive 
ICA in patients at onset of IDDM were more frequently 
present in GAD-positive sera than in those sera negative 
for GAD, this seems to be no general phenomenon. 
Identification of further target antigens of ICA will allow us 
to determine the significance that the diverse non-GAD-
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reactive ICAs have as markers for autoimmune insulitis 
and as potential contributors to the development of 
IDDM. 
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